Breakthrough in Gastric Cancer Treatment
The MATTERHORN trial has revealed a new approach to biomarker use in early gastric and GEJ cancer treatment.
Nancy Ghattas, VP of US Oncology Commercial Franchise Head of Immuno-Oncology at AstraZeneca, discussed the trial's results, highlighting the significance of a 22% reduction in the risk of death.
The Imfinzi-based perioperative regimen demonstrated improved overall survival regardless of PD-L1 status.
This marks the first immunotherapy in this setting to show such benefit, potentially expanding access to immunotherapy.
Key Findings
- 22% reduction in the risk of death
- Improved overall survival regardless of PD-L1 status
AstraZeneca's Nancy Ghattas shares insights on the trial's results and their implications for biomarker strategies.
Author's summary: Breakthrough trial results reshape gastric cancer treatment.